An intact PDZ motif is essential for correct P2Y12 purinoceptor traffic in human platelets

被引:38
|
作者
Nisar, Shaista [1 ]
Daly, Martina E. [2 ]
Federici, Augusto B. [3 ]
Artoni, Andrea [4 ]
Mumford, Andrew D. [5 ]
Watson, Stephen P. [6 ]
Mundell, Stuart J. [1 ]
机构
[1] Univ Bristol, Sch Physiol & Pharmacol, Bristol BS8 1TD, Avon, England
[2] Univ Sheffield, Dept Cardiovasc Sci, Haemostasis Res Grp, Sheffield, S Yorkshire, England
[3] Univ Milan, Dept Internal Med, L Sacco Univ Hosp, Angelo Div Haematol & Transfus Med, Milan, Italy
[4] Regina Elena Fdn, Carattere Sci Maggiore Policlin Hosp, Ist Ricovero & Cura, Angelo Bianchi Bonomi Haemophilia & Thrombosis Ct, Milan, Italy
[5] Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS8 1TD, Avon, England
[6] Univ Birmingham, Coll Med & Dent Sci, Ctr Cardiovasc Sci, Birmingham, W Midlands, England
关键词
PROTEIN-COUPLED RECEPTORS; VON-WILLEBRAND-DISEASE; CLATHRIN-COATED PITS; DEPENDENT MECHANISMS; PATIENT; BETA; ENDOCYTOSIS; SIGNAL; INTERNALIZATION; TRANSDUCTION;
D O I
10.1182/blood-2011-02-336826
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The platelet P2Y(12) purinoceptor (P2Y(12)R), which plays a crucial role in hemostasis, undergoes internalization and subsequent recycling to maintain receptor responsiveness, processes that are essential for normal platelet function. Here, we observe that P2Y(12)R function is compromised after deletion or mutation of the 4 amino acids at the extreme C-terminus of this receptor (ETPM), a putative postsynaptic density 95/disc large/zonula occludens-1 (PDZ)-binding motif. In cell line models, removal of this sequence or mutation of one of its core residues (P341A), attenuates receptor internalization and receptor recycling back to the membrane, thereby blocking receptor resensitization. The physiologic significance of these findings in the regulation of platelet function is shown by identification of a patient with a heterozygous mutation in the PDZ binding sequence of their P2Y(12)R (P341A) that is associated with reduced expression of the P2Y(12)Ron the cell surface. Importantly, platelets from this subject showed significantly compromised P2Y(12)R recycling, emphasizing the importance of the extreme C-terminus of this receptor to ensure correct receptor traffic. (Blood. 2011;118(20):5641-5651)
引用
收藏
页码:5641 / 5651
页数:11
相关论文
共 50 条
  • [31] New P2Y12 antagonists
    Michelson, Alan D.
    CURRENT OPINION IN HEMATOLOGY, 2009, 16 (05) : 371 - 377
  • [32] 'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists
    Glenn, Jacqueline R.
    Dovlatova, Natalia
    White, Ann E.
    Dhillon, Kiren
    Heptinstall, Stan
    Fox, Susan C.
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (03) : 539 - 548
  • [33] New P2Y12 Inhibitors
    Cattaneo, Marco
    CIRCULATION, 2010, 121 (01) : 171 - 179
  • [34] P2Y12 inhibitors for the neurointerventionalist
    Borchert, Robin J.
    Simonato, Davide
    Hickman, Charlotte
    Fuschi, Maurizio
    Thibault, Lucie
    Henkes, Hans
    Fiorella, David
    Tan, Benjamin Y. Q.
    Yeo, Leonard L. L.
    Makalanda, Hegoda L.
    Wong, Ken
    Bhogal, Pervinder
    INTERVENTIONAL NEURORADIOLOGY, 2022, 28 (01) : 92 - 103
  • [35] Dual Therapy (P2Y12
    Franke, Katharina
    AKTUELLE KARDIOLOGIE, 2019, 8 (04) : 256 - 256
  • [36] Canine Cancer Cells Activate Platelets via the Platelet P2Y12 Receptor
    Bulla, Sandra C.
    Badial, Peres R.
    Bulla, Camilo
    JOURNAL OF COMPARATIVE PATHOLOGY, 2022, 192 : 41 - 49
  • [37] Inhibiting The P2Y12 Receptor In Megakaryocytes And Platelets Suppresses Interferonassociated Inflammatory Responses
    Sowa, Marcin A.
    Wang, Tricia T.
    Schlamp, Florencia
    Cornwell, Macintosh
    El Bannoudi, Hanane
    Hannah, Bash
    Clancy, Robert
    Ruggles, Kelly
    Buyon, Jill
    Voora, Deepak
    Barrett, Tessa J.
    Berger, Jeffrey S.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [38] Inhibiting the P2Y12 12 Receptor in Megakaryocytes and Platelets Suppresses Interferon-Associated Responses
    Sowa, Marcin A.
    Sun, Haoyu
    Wang, Tricia T.
    Virginio, Vitor W.
    Schlamp, Florencia
    El Bannoudi, Hanane
    Cornwell, MacIntosh
    Bash, Hannah
    Izmirly, Peter M.
    Belmont, H. Michael
    Ruggles, Kelly, V
    Buyon, Jill P.
    Voora, Deepak
    Barrett, Tessa J.
    Berger, Jeffrey S.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2024, 9 (09): : 1126 - 1140
  • [39] P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor
    Kim, Juwon
    Jang, Woo Jin
    Lee, Wang Soo
    Choi, Ki Hong
    Lee, Joo Myung
    Park, Taek Kyu
    Yang, Jeong Hoon
    Choi, Jin-Ho
    Bin Song, Young
    Choi, Seung-Hyuk
    Gwon, Hyeon-Cheol
    Lee, Sang Hoon
    Oh, Ju-Hyeon
    Chun, Woo Jung
    Park, Yong Hwan
    Im, Eul-Soon
    Jeong, Jin-Ok
    Cho, Byung Ryul
    Oh, Seok Kyu
    Yun, Kyeong Ho
    Cho, Deok-Kyu
    Lee, Jong-Young
    Koh, Young-Youp
    Bae, Jang-Whan
    Choi, Jae Woong
    Yoon, Hyuck Jun
    Lee, Seung Uk
    Cho, Jang Hyun
    Choi, Woong Gil
    Rha, Seung-Woon
    Hahn, Joo-Yong
    HEART, 2021, 107 (13) : 1077 - 1083
  • [40] Effect of immature platelets on ADP-induced platelet reactivity after infusion of the P2Y12 receptor inhibitor cangrelor and transitioning to oral P2Y12 inhibitors
    Stratz, C.
    Nuhrenberg, T.
    Kleiner, P.
    Leggewie, S.
    Neumann, F. J.
    Hochholzer, W.
    Trenk, D.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2017, 390 : S23 - S23